LDL

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Cat.No.	Product Name	Information	Product Use Citations
S1655	Ezetimibe (SCH-58235)	Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor that is used to lower cholesterol.	J Med Chem, 2025, 68(2):1179-1194 Toxicol Lett, 2025, 406:31-37 J Immunother Cancer, 2024, 12(11)e009805
S2119	Probucol	Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.	J Immunother Cancer, 2024, 12(11)e009805 Int Immunopharmacol, 2023, 116:109820
E3811	Cashew Extract	Cashew Extract is extracted from Anacardium occidentale, which lowers the levels of LDL cholesterol and may help to prevent heart disease due to its high magnesium content.
S9187	Phillygenin	Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
S7953	Bempedoic acid (ETC-1002)	Bempedoic acid (ETC-1002) is an orally available, once-daily LDL-C lowering small molecule designed to reduce elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. This compound is an activator of hepatic AMP-activated protein kinase (AMPK) and has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).	Cancer Cell, 2025, 43(4):776-796.e14 iScience, 2023, 26(12):108532 Oncol Rep, 2023, 49(2)32
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, and does not increase aldosterone or blood pressure. This compound is in Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62